Goodbye to anxiety about pulmonary nodules! A drop of blood can test for 13 types of lung cancer. The new early diagnosis kit in China has been approved and launched on the market.

Thirteen lung cancer-related antibody detection test kits developed by researcher Hu Hai, associate director of the Nucleic Acid Molecular Medicine Center and academic vice president of the Affiliated Tumor Hospital of the Hangzhou Institute of Medicine of the Chinese Academy of Sciences, have officially obtained the Class III Medical Device Registration Certificate from the National Medical Products Administration. This makes it the world's first auxiliary diagnostic kit for distinguishing between benign and malignant lung nodules detected by CT scans, with the potential to significantly improve the early diagnosis rate of lung cancer. The team used a million-level cancer tissue library and multimodal high-throughput screening technology, combined with synthetic biology methods, to recombinantly express more than 400 early key proteins in lung cancer. Finally, through the use of their independently developed liquid suspension chip technology and artificial intelligence algorithms, they screened out 13 optimal diagnostic marker combinations. Among them, 8 are new combinations of markers that far exceed current clinical application levels.